Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced or Metastatic ER+ Breast Cancer
Interventions: DRUG: LSZ102|DRUG: LEE011|DRUG: BYL719
Sponsor: Novartis Pharmaceuticals